Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Abstract

Nonalcoholic fatty liver disease (NAFLD, including nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH)) is a high-prevalence disorder, affecting about 1 billion people, which can evolve to more severe conditions like cirrhosis or hepatocellular carcinoma. NAFLD is often concomitant with conditions of the metabolic syndrome, such as central obesity and insulin-resistance, but a specific drug able to revert NAFL and prevent its evolution towards NASH is still lacking. With the liver being a key organ in metabolic processes, the potential therapeutic strategies are many, and range from directly targeting the lipid metabolism to the prevention of tissue inflammation. However, side effects have been reported for the drugs tested up to now. In this review, different approaches to the treatment of NAFLD are presented, including newer therapies and ongoing clinical trials. Particular focus is placed on the reverse cholesterol transport system and on the agonists for nuclear factors like PPAR and FXR, but also drugs initially developed for other conditions such as incretins and thyromimetics along with validated natural compounds that have anti-inflammatory potential. This work provides an overview of the different therapeutic strategies currently being tested for NAFLD, other than, or along with, the recommendation of weight loss.

Unveiling the mitophagy puzzle in non-alcoholic fatty liver disease (NAFLD): Six hub genes for early diagnosis and immune modulatory roles

“…Previous research has established the critical roles of lipid metabolism and mitochondrial function in NAFLD[ [39] , [40] ]. In our study, we combined three datasets (GSE49541, GSE89632, and GSE63067) and performed GSEA.…”

Metabolic Insights into Caffeine’s Anti-Adipogenic Effects: An Exploration through Intestinal Microbiota Modulation in Obesity

“…This suppression promoted de novo lipogenesis and lipid β-oxidation through the activation of PPARα [164]. Furthermore, it is known that the upregulation of PPARα through FXR stimulates free fatty acids β-oxidation and, consequently, a reduction in VLDL [165]. The decrease in triglycerides associated with the upregulation of O-acylcarnitine suggests an increase in FFA β-oxidation and a consequent improvement in the lipid profile and related metabolic syndromes [166].…”

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

“…A family of nuclear receptors, the peroxisome proliferator-activated receptors (PPARs), are involved as transcription factors in various processes of lipid and glucose metabolism and inflammation [84,85]. Moreover, they appear to be involved in fibrotic processes, as agonism of the PPAR isotope gamma (γ) leads to an inhibition of the pro-fibrotic effect of hepatic stellate cells in the liver, which are activated in the course of NASH progression [86].…”